IMCR Stock Overview
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immunocore Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.28 |
| 52 Week High | US$76.98 |
| 52 Week Low | US$29.72 |
| Beta | 0.72 |
| 11 Month Change | -1.59% |
| 3 Month Change | -12.52% |
| 1 Year Change | -29.72% |
| 33 Year Change | -11.27% |
| 5 Year Change | n/a |
| Change since IPO | -25.28% |
Recent News & Updates
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Oct 24
Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Sep 19Recent updates
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Oct 24Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Sep 19Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Aug 12Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Jul 24Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Jun 16Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
May 11Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Apr 05Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
Jan 22Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Jan 21Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Dec 18Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S
May 08Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically
Nov 16Immunocore: Attractive Commercial-Stage Biopharma
Oct 05Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)
Aug 12Immunocore GAAP EPS of -$0.17, revenue of $38.92M
Aug 10Immunocore to raise $140M in private placement financing
Jul 18Shareholder Returns
| IMCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.2% | 2.5% | 2.2% |
| 1Y | -29.7% | 16.1% | 31.6% |
Return vs Industry: IMCR underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: IMCR underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| IMCR volatility | |
|---|---|
| IMCR Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMCR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMCR's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 497 | Bahija Jallal | www.immunocore.com |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Immunocore Holdings plc Fundamentals Summary
| IMCR fundamental statistics | |
|---|---|
| Market cap | US$1.62b |
| Earnings (TTM) | -US$47.05m |
| Revenue (TTM) | US$296.31m |
5.5x
P/S Ratio-34.3x
P/E RatioIs IMCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMCR income statement (TTM) | |
|---|---|
| Revenue | US$296.31m |
| Cost of Revenue | US$208.75m |
| Gross Profit | US$87.56m |
| Other Expenses | US$134.61m |
| Earnings | -US$47.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 29.55% |
| Net Profit Margin | -15.88% |
| Debt/Equity Ratio | 116.1% |
How did IMCR perform over the long term?
See historical performance and comparison